Viro-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression

Autor: Anna Danise, Raffaele Dell’Acqua, Antonella Castagna, Laura Galli, Nicola Gianotti, Silvia Nozza, Daniela Zandona, P Tadini, Adriano Lazzarin, Andrea Mastrangelo, Andrea Poli, Monica Guffanti
Přispěvatelé: Dell'Acqua, R., Galli, L., Poli, A., Mastrangelo, A., Guffanti, M., Tadini, P., Zandona, D., Danise, A., Gianotti, N., Lazzarin, A., Castagna, A., Nozza, S.
Rok vydání: 2019
Předmět:
0301 basic medicine
Adult
Male
medicine.medical_specialty
13-valent pneumococcal conjugate vaccine
Sustained Virologic Response
Anti-HIV Agents
Immunology
Human immunodeficiency virus (HIV)
HIV Infections
medicine.disease_cause
Pneumococcal conjugate vaccine
Pneumococcal Infections
Pneumococcal Vaccines
03 medical and health sciences
0302 clinical medicine
Interquartile range
confirmed virological failure
Internal medicine
vaccine
Immunology and Allergy
Medicine
Humans
030212 general & internal medicine
Treatment Failure
Viremia
Retrospective Studies
business.industry
Pneumococcal conjugate vaccination
Middle Aged
Viral Load
HIV infection
Confidence interval
CD4 Lymphocyte Count
Vaccination
030104 developmental biology
Infectious Diseases
Italy
Pneumococcal vaccination
viral blip
HIV-1
Female
business
virological suppression
Cohort study
medicine.drug
Zdroj: AIDS (London, England). 33(13)
ISSN: 1473-5571
Popis: Background:Very limited data are available on the immunovirological outcomes after 13-valent pneumococcal conjugate vaccine (PCV13) in antiretroviral therapy (ART)-treated patients. The aim of this study was to assess the immune-virological outcomes in HIV-1-infected ART-treated patients on stable virological suppression who underwent pneumococcal conjugate vaccination.Methods:Retrospective, cohort study on ART-treated HIV-1-infected individuals, age at least 18 years, with three consecutive determinations of HIV-RNA less than 50 copies/ml before the administration of PCV13 (baseline) at San Raffaele Hospital and with at least two HIV-RNA values after vaccination.Results:Overall 1197 patients underwent PCV13 vaccination. During 6-month of follow-up (594 person-years of follow-up, PYFU), 12 confirmed virological failure and 35 viral blips were observed; the overall incidence rate of confirmed virological failure was 2.02 (95% confidence interval: 0.88-3.16) per 100-PYFU and the incidence rate of viral blips was 5.89 (95% confidence interval: 3.94-7.84) per 100-PYFU. Median CD4+ cell count change from baseline at 6 months was +10 cells/μl (interquartile range -67, +111; P = 0.0002). Median change in CD4+/CD8+ ratio was +0.02 (interquartile range -0.06, +0.11; P < 0.001).Conclusion:Viral blips and confirmed virological failures were rarely observed in patients on stable virological suppression in the first 6 months following vaccination with PCV13. In addition, no decrease of CD4+ cell count and CD4+/CD8+ ratio was recorded.
Databáze: OpenAIRE
Externí odkaz: